Search

What Would You Do? Engaging in Evidence-based Treatment Approaches for Multiple Sclerosis

Release Date: June 28, 2024

Valid for Credit through: June 28, 2024

This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education.

This activity is supported by independent educational grants from
EMD Serono and Mylan Specialty L.P., a Viatris Company.

Credit Available
  • Physicians — maximum of 1.5 AMA PRA Category 1 Credits
  • Nurses — 1.5 nursing continuing professional development (NCPD) credits (1.5 in the area of pharmacology)
  • Pharmacists — 1.5 contact hours (.15 CEU) of continuing pharmacy education credit

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for neurologists, advanced practice clinicians, nurses, pharmacists, and other members of the health care professional team who care for people with MS.

Program Overview

Decision-making in multiple sclerosis (MS) care is as complex as the disease itself. Understanding of the inflammatory and neurodegenerative processes implicated in disease activity and progression continues to improve. At the same time, technology is constantly progressing. These advances are driving changes in the way MS is viewed and managed across the continuum of disease. As evidence evolves, clinicians look to experts for guidance and best practices. This case-based session is designed to highlight current challenges in the diagnosis, treatment, and monitoring of people with MS. Expert faculty will present cases, discuss relevant evidence, explore options, and provide their answers to the question “what would you do?”

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Apply criteria, appropriate tools, and best practices when considering a diagnosis of MS
  • Discuss evolving concepts related to traditional and potentially emerging measures of disease activity and progression
  • Select appropriate pharmacologic and/or nonpharmacologic treatments for MS-related symptoms
  • Examine the role of aging in MS and its impact on disease course and treatment
Faculty

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs) Department of Neurology
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, New York

Amy Perrin Ross, APN, CNRN, MSCN
Neuroscience Consultant
Chicago, Illinois

Physician Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC), and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Physician Credit Designation

The CMSC designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The CMSC designates this activity for a maximum of 1.5 nursing continuing professional development (NCPD) credits (1.5 in the area of pharmacology).

Pharmacists Credit Designation

This knowledge-based activity, UAN JA4008165-9999-24-007-H01-P, qualifies for 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit.

All other health care professionals completing this course will be issued a statement of participation.

Contact Information

For questions about this activity, please contact Catamount Medical Education at [email protected].